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Genetic Mapping with Multiple Levels
of Phenotypic Information Reveals Determinants
of Lymphocyte Glucocorticoid Sensitivity
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and Anna Di Rienzo1,2,*
Clinical response to glucocorticoids, steroid hormones widely used as pharmaceuticals, varies extensively in that many individuals
(~30%) show a weak response to treatment. Although little is known about the molecular basis of this variation, regulatory polymor-
phisms are likely to play a key role given that glucocorticoids act largely through activation of a transcription factor, the glucocorticoid
receptor. In an effort to characterize the molecular basis of variation in glucocorticoid sensitivity, we measured in vitro lymphocyte
glucocorticoid sensitivity and transcriptome-wide response to glucocorticoids in peripheral-blood mononuclear cells from African
American healthy donors.We found that variation in lymphocyte glucocorticoid sensitivity was correlatedwith transcriptional response
at 27 genes (false-discovery rate < 0.1). Furthermore, a genome-wide association scan revealed a quantitative trait locus (QTL) for
lymphocyte glucocorticoid sensitivity (rs11129354, p¼ 43 108); it was also associated with transcriptional response at multiple genes,
including many (14/27) where transcriptional response was correlated with lymphocyte glucocorticoid sensitivity. Using allelic-
imbalance assays, we show that this QTL is a glucocorticoid-dependent cis-regulatory polymorphism for RBMS3, which encodes an
RNA-binding protein known as a tumor suppressor. We found that siRNA-mediated knockdown of RBMS3 expression increased cellular
proliferation in PBMCs, consistent with the role of the gene as a negative regulator of proliferation. We propose that differences in
lymphocyte glucocorticoid sensitivity reflect variation in transcriptional response, which is influenced by a glucocorticoid-dependent
regulatory polymorphism that acts in cis relative to RBMS3 and in trans to affect the transcriptional response of multiple distant genes.Glucocorticoids are endogenous steroid hormones that are
also widely used as therapeutic agents to treat a variety of
diseases, such as asthma,1–3 inflammatory bowel disease,4
and lymphoid malignancies.5 Although glucocorticoids
are among the most widely used and successful drugs in
history,6 clinical response to glucocorticoids is highly
variable7,8 in that a substantial fraction of individuals
(~30%) show a weak response to treatment.9–11 Glucocor-
ticoids exert their effects on target cells primarily through
the regulation of gene expression12 after activation of the
glucocorticoid receptor (GR), a transcription factor.
Interindividual variation in response to glucocorticoid
therapy is likely to reflect differences in transcriptional
response across individuals. Indeed, we and others have
previously shown that glucocorticoid-mediated changes
in gene expression are correlated with in vitro13 and
clinical measures14 of glucocorticoid response.
Although environmental factors undoubtedly play an
important role, there is also evidence of a genetic contribu-
tion to variation in glucocorticoid response.8,15,16 Several
polymorphisms, including polymorphisms in genes that
encode the GR17–19 and other major regulatory proteins
involved in glucocorticoid response,20,21 have been impli-
cated in variable response to glucocorticoids. Most of these
are rare variants that explain severe cases of nonresponse
and therefore contribute little to common variation in
glucocorticoid sensitivity.8 Candidate-gene studies have
also identified associations with glucocorticoid response1Committee on Clinical Pharmacology and Pharmacogenomics, The Universit
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The Americin individuals with asthma, but these polymorphisms
explain little of the common variation in glucocorticoid
response and/or are unreliably associated with response
(reviewed in Tantisira et al.22). In an effort to move beyond
candidate genes, several recent studies have performed
genome-wide association mapping of glucocorticoid
response in individuals with asthma, revealing associa-
tions at a cis-regulatory polymorphism for GLCCI122
(MIM 614283) and a polymorphism in T23 (MIM
601397). These studies demonstrate the importance of
genome-wide scans for identifying novel polymorphisms
that influence glucocorticoid sensitivity.
To interrogate the genetic and regulatory basis of varia-
tion in glucocorticoid sensitivity, we measured in vitro
lymphocyte glucocorticoid sensitivity and transcriptome-
wide response to glucocorticoids in peripheral-blood
mononuclear cells (PBMCs) from 88 African American
(AA) healthy donors. At the time of blood draw, donors
were asked to fill out a medical and medication history
questionnaire, and only donors who self-reported as not
having recent illnesses or ailments (chronic or acute)
were included. Research Blood Components requires that
all donors sign an institutional-review-board-approved
consent form giving permission for the collection, use,
and/or sale of blood for research purposes. Blood samples
were not shipped to the University of Chicago with indi-
vidually identifiable information. PBMCs were cultured
at 2 3 105 cells per well in 10% charcoal-stripped mediay of Chicago, 900 East 57th Street, Chicago, IL 60637, USA; 2Department of
60637, USA
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in 96-well plates and treated in triplicate (themedian value
was used) with phytohemagglutinin (PHA) (2.5 mg/ml) and
either a vehicle (EtOH) or dexamethasone (dex) (1 mM,
0.1 mM, 10 nM, or 1 nM). H3-thymidine incorporation
was used for measuring cell proliferation after 48 hr of
treatment. Lymphocyte glucocorticoid sensitivity has
been shown to be correlated with clinical response to
glucocorticoid therapy in individuals with a wide range
of diseases, including asthma,24–28 rheumatoid arthritis,29
systemic lupus erythematosous,30 ulcerative colitis,31 and
renal transplant rejection,32 as well as with risk of devel-
oping posttraumatic stress disorder.33 The reported
correlations between in vitro lymphocyte glucocorticoid
sensitivity and clinical response in diseases affecting
different tissues suggest that glucocorticoid nonrespon-
siveness is mediated by lymphocytes or that the in vitro
assay captures sharedmechanisms of glucocorticoid action
across cell types, making this an appropriate experimental
system for investigating the molecular basis of glucocorti-
coid resistance. Interestingly, patterns of variation in
in vitro lymphocyte glucocorticoid sensitivity among indi-
viduals with diseases that are treated with glucocorticoids
are similar to those observed in healthy donors: they
have similar proportions of nonresponsive individuals
and similar interethnic differences in response.13,31,34
This suggests that glucocorticoid sensitivity is a property
of the general population and manifests itself as clinical
resistance when individuals develop a disease for which
glucocorticoids are administered. Here, we investigate the
molecular basis of variation in in vitro lymphocyte gluco-
corticoid sensitivity, allowing us to explore general mech-
anisms of glucocorticoid resistance without limiting
ourselves to a particular disease or tissue. We note, how-
ever, that this approach cannot identify glucocorticoid-
resistance mechanisms that are specific to other cell types
or other experimental conditions. Although a variety of
metrics (e.g., IC50, a measure of potency) have been corre-
lated with clinical response,24–33 percent inhibition at a
high dose (e.g., Imax, a measure of efficacy) was previ-
ously shown to be particularly strongly correlated.31 We
measured both Imax and IC50 in each donor. We found
that age, gender, circulating cortisol levels (catalog no.
11875116160, Roche Diagnostics), baseline GR transcript
levels, and basal PBMC proliferation levels were not signif-
icantly correlated with Imax or IC50, consistent with previ-
ous results.13,31 We also measured PBMC composition in
each donor by using flow cytometry with the following an-
tibodies: anti-CD3-PE-Cy7 to mark T cells (BDB560910),
anti-CD14-FITC to mark monocytes (NC0088365),
anti-CD20-PE to mark B cells (BDB555623), anti-CD4-
PerCP-Cy5.5 to mark T helper cells (BDB560650), and
anti-CD8-APC to mark cytotoxic T cells (COIM2469). All
antibodies were obtained from Fisher Scientific. We found
a significant and negative correlation between Imax and the
proportion of CD8þ T cells (p ¼ 0.024). This is consistent
with clinical studies that show that CD8þ T cell propor-
tions are correlated with insensitivity to glucocorticoid736 The American Journal of Human Genetics 93, 735–743, Octobertreatment in individuals with multiple myeloma35 and
systematic lupus erythematosus.36 Both Imax and IC50
were corrected for all covariates above in all subsequent
analyses.
To interrogate the role of transcriptional response in
variable glucocorticoid sensitivity, we profiled gene expres-
sion in the presence of either dex or vehicle after 6 hr of
treatment in PHA-treated PBMCs from 85 of the same 88
healthy donors assayed, in parallel, for lymphocyte gluco-
corticoid sensitivity. PBMCs from each donor were grown
in 24-well plates (106 cells per well) and treated with PHA
(2.5 mg/ml) and either vehicle (EtOH) or dex (1 mM) in
three replicates that were pooled before RNA extraction.
Total RNA was extracted from each pool with the RNeasy
Plus Mini Kit (QIAGEN 74134). Expression was profiled
with Illumina HumanHT-12 v4 Expression BeadChips.
Low-level microarray analysis was performed with the
Bioconductor software package LUMI37 in R, including
variance-stabilizing transformation,38 filtering based on
expression levels, and quantile normalization across all
arrays. Probes were annotated by mapping to the mRNA
sequences from RefSeq with the use of BLAT, and probes
that mapped to multiple genes or that contained one or
more HapMap SNPs were excluded from further analyses.
The microarray data have been deposited in the Gene
Expression Omnibus (GEO) under accession number
GSE48801. We used linear regression to identify genes
that were differentially expressed between dex- and
vehicle-treated samples and controlled for potential covari-
ates (i.e., batch, age, gender, cell proportions, time of blood
draw, and cortisol levels). Similarly to previous studies of
glucocorticoid response in PBMCs13,14 and other cell
types,39,40 we found a large number of genes differentially
expressed between dex- and vehicle-treated samples
(6,296; false-discovery rate [FDR] < 0.01, Figure S1, avail-
able online). (FDRs were estimated with the q value func-
tion41 in R.)
To assess the effect of PHA stimulation on the transcrip-
tome, we also compared gene expression between PHA-
treated and PHA-untreated PBMCs from 9 of the 85
donors. Because we measured expression in the absence
of PHA in a much smaller set of samples, we used a hierar-
chical model to stabilize estimates of the variance
(LIMMA42 in R) to identify genes differentially expressed
between PHA- and blank-treated samples. We found that
3,640 genes were differentially expressed (FDR < 0.01,
Figure S1) after PHA stimulation. We used the Database
for Annotation, Visualization, and Integrated Discovery
(DAVID)43,44 to identify gene sets enriched among differ-
entially expressed genes (by using all genes expressed in
PBMCs as a background), which revealed that genes upre-
gulated in PHA-stimulated PBMCs were enriched with
gene sets consistent with the proinflammatory properties
of PHA (Table S1); these gene sets included pathways
related to both adaptive (e.g., ‘‘regulation of T cell activa-
tion,’’ p ¼ 5.4 3 109, FDR ¼ 1.7 3 106) and
innate (e.g., ‘‘innate immune response,’’ p ¼ 1.9 3 104,3, 2013
Figure 1. Results of the GWAS for Imax
(A) Regional association plot showing log10 p values (y axis) by genomic position (x axis) for variants within 400 kb of the most
associated variant, rs11129354. The inset below the x axis depicts the position of genes within this region. This plot was made with
LocusZoom.47
(B) Box plots of Imax by genotype at rs11129354.FDR¼ 8.83103) immune response.Downregulated genes
were enrichedwith biological processes related to cell death
(e.g., ‘‘lysosome,’’ p ¼ 3.3 3 106, FDR ¼ 5.9 3 104, Table
S2). Consistent with dex inhibition of PHA-mediated cell
proliferation, 3,000 of the 3,640 genes differentially ex-
pressed in the presence of PHA (FDR < 0.01) were also
differentially expressed after dex treatment (FDR < 0.01).
Consistent with the inhibitory effect of glucocorticoids
on PHA-mediated cell proliferation, dex treatment largely
reversed the transcriptional effects of PHA: considering
only the genes differentially expressed in both treatments
(FDR < 0.01), 91.7% of genes upregulated by PHA were
downregulated by glucocorticoids and 88.1% of genes
downregulated by PHA were upregulated after glucocorti-
coid treatment (Figure S1). We found that genes that were
differentially expressed by PHA treatment (FDR < 0.01)
and not differentially expressed by glucocorticoid treat-
ment (p > 0.05) were significantly enriched with the
Panther glycolysis pathway (p ¼ 4.1 3 104, FDR ¼
0.037). PHA is known to increase glycolysis in lympho-
cytes,45 and this result suggests that this mechanism is
not modified by glucocorticoid treatment.
We then turned to the relationship between transcrip-
tional response to glucocorticoids and lymphocyte gluco-
corticoid sensitivity. For these comparisons, we used the
log2 fold change in expression between dex- and vehicle-
treated samples as a measure of transcriptional response
for each gene in each donor. To identify genes with expres-
sion patterns predictive of lymphocyte glucocorticoid
sensitivity, we used linear regression to test for an associa-
tion between Imax and log2 fold change at each gene while
controlling for log2 fold change at NFKB1 (MIM 164011),
which has been previously shown to be associated with
glucocorticoid sensitivity.13,14 Log2 fold change at 27 genes
was significantly associated with Imax (FDR < 0.1). TheseThe Americinclude genes with clear relevance to immune response,
such as pre-B lymphocyte 3 (VPREB3 [MIM 605017]), an
immunoglobulin receptor component and mediator of B
cell differentiation. We also found 85 genes for which
log2 fold change was significantly associated with IC50
(FDR < 0.1). These also included genes with established
roles in the lymphocyte-mediated immune response,
such as interleukin-12 receptor, beta 1 (IL12RB1 [MIM
601604]) and chemokine (C-C motif) receptor 3 (CCR3
[MIM 601268]).
To interrogate the genetic basis of variation in glucocor-
ticoid sensitivity, we used Illumina Omni BeadChips (58
on Omni1-Quad and 32 on Omni2.5-Quad) to genotype
884,015 SNPs across the genome for each donor and
then imputed polymorphisms identified in the 1000
Genomes Project.46 The genotype data are available from
the authors upon request. All donors had genotype call
rates greater than or equal to 0.995. No pair of these 88
donors showed closer than first-cousin relatedness (on
the basis of donor-relatedness tests performed with
PLINK). After filtering for minor allele frequency (>0.1),
imputation quality (>0.9), departure from Hardy-
Weinberg equilibrium (p > 0.05), and differences in allele
frequency between genotyping-array platforms (p >
0.05), we had a set of 3,952,978 variants. We then used
these markers to perform genome-wide association studies
(GWASs) for both Imax and IC50. To avoid spurious associa-
tions due to population structure, we controlled for
genome-wide proportions of African ancestry in our
association tests. We found a genome-wide significant
association (p < 5 3 108) between genotype at
rs11129354 and Imax (p ¼ 4 3 108, Figure 1). Explaining
26% of variation in our sample, this QTL had a relatively
large effect on Imax (Figure 1). In contrast, we found no
genome-wide significant associations for IC50.an Journal of Human Genetics 93, 735–743, October 3, 2013 737
Figure 2. Evidence of Association between Genotype and
Transcriptional Response at Genes Correlated with Imax
Histograms of p values for association between log2 fold change
(‘‘LFC’’) and genotype at rs11129354 at genes where log2 fold
change was suggestively correlated with Imax (p < 0.1, red bars)
and where log2 fold change was not suggestively associated
(p > 0.1, black bars).We hypothesized that rs11129354 influenced lympho-
cyte glucocorticoid sensitivity through effects on transcrip-
tional response at one or more genes. To explore this
possibility, we tested for an association between genotype
at this QTL and log2 fold change at each of the 9,995 genes
that were suggestively associated with Imax (p < 0.1). SNP
rs11129354 was associated with log2 fold change at 161
genes (FDR < 0.1, Figure 2). Furthermore, the genes most
strongly associated with Imax were much more likely to
be influenced by genotype at rs11129354 than were other
genes expressed in PBMCs. For example, 14 of the 27 genes
that were genome-wide significantly associated with Imax
were also marginally associated with genotype at
rs1112954 (odds ratio ¼ 13.5, p ¼ 1.2 3 109). To test an
alternative model in which rs11129354 influences
lymphocyte glucocorticoid sensitivity through another
mechanism and lymphocyte glucocorticoid sensitivity, in
turn, affects log2 fold change at these genes, we used
multiple linear regression to assess the effect of controlling
for Imax on the association between genotype at
rs11129354 and log2 fold change. (To avoidmulticollinear-
ity, we corrected Imax for genotype at rs11129354 before
including it in the model.) We found that our data were
not consistent with this alternative model, given that con-
trolling for lymphocyte glucocorticoid sensitivity did not
diminish the strength of association (Table S3 and
Figure S2). These results provide strong statistical evidence
that rs11129354 is itself, or linked to, a trans-acting regula-
tory polymorphism that interacts with treatment in the
regulation of expression at multiple genes to eventually
influence overall cellular sensitivity to glucocorticoids.738 The American Journal of Human Genetics 93, 735–743, OctoberWe then turned to the molecular processes that underlie
the association between rs11129354 and Imax. SNP
rs11129354 lies 68 kb downstream of RBMS3 (MIM
605786), which encodes an RNA-binding protein. Previous
studies have identified this gene as a negative regulator of
proliferation in other tissues. RBMS3 is deleted in many
tumor cell types,48–50 suggesting that it encodes a tumor
suppressor. In addition, experimental evidence has
shown that RBMS3 inhibits cellular proliferation in esoph-
ageal squamous cell carcinoma51 and nasopharyngeal
carcinoma.52 Furthermore, RBMS3 encodes an RNA-bind-
ing protein belonging to the family of MYC (MIM
190080) single-strand binding proteins, which are known
to regulate cell-cycle progression and apoptosis
through the regulation of gene expression.53 Specifically,
RBMS3 is localized in the cytoplasm and regulates
target-gene expression posttranscriptionally through RNA
binding.51,54,55 However, its role in the regulation of the
transcriptional response to glucocorticoids has not previ-
ously been identified.
We hypothesized that rs11129354 influences Imax
through treatment-specific cis-acting regulatory effects on
RBMS3 expression. Microarray intensity measurements
for RBMS3 were below the detection threshold in our
data, most likely because the probe for this gene only
tagged two of five isoforms. To profile all transcripts for
RBMS3, we designed primers that tagged all five isoforms
of RBMS3 (forward: 50-GGAACTAGCGAGTGGTGGAG-30;
reverse: 50-GGTGCATAGGACTGCTTGGT-30) and used
RT-PCR to assay expression in the presence and absence
of glucocorticoids in 20 donors (ten of each homozygous
genotype at rs11129354). We found a significant
association between log2 fold change at RBMS3 and geno-
type at rs11129354 (p ¼ 9.8 3 103, Figure 3). To directly
interrogate the possibility that rs11129354 is a cis-acting
regulatory polymorphism with treatment-specific effects,
we then assayed treatment-dependent allelic imbalance
by using TaqMan assays for a coding SNP (rs6549965)
in RBMS3 in 32 donors who were heterozygous at
rs6549965 (16 were heterozygous at rs11129354, and 16
were homozygous at rs11129354). We found significant
allelic imbalance (allelic effects were consistent with those
observed on overall transcript levels) in glucocorticoid-
treated samples (p ¼ 0.044, Figure 3), but not in control-
treated samples (p ¼ 0.88, Figure 3). These results are
consistent with a model where rs11129354 affects
transcriptional response through cis-regulatory effects on
RBMS3, which in turn mediates effects in trans on
transcriptional response at other genes and ultimately
influences lymphocyte proliferation. To directly test the
hypothesis that RBMS3 affects lymphocyte glucocorticoid
sensitivity, we transfected PBMCs with either a pool of
four siRNAs that targeted the RBMS3 transcript (Dharma-
con L-013725-00-0005) or a pool of four nontargeting
negative controls (Dharmacon D-001810-10-05). Consis-
tent with our model above, we found that knockdown
of the RBMS3 transcript led to a dramatic increase in3, 2013
Figure 3. Rs11129354 Acts as a Gluco-
corticoid-Specific cis-Regulatory Polymor-
phism for RBMS3, which Is a Negative
Regulator of Proliferation
(A) Box plot showing the distribution of
log2 fold change at RBMS3 by genotype at
rs11129354. We used quantitative RT-
PCR to profile RBMS3 expression for this
analysis given that we found that micro-
array intensity measurements were below
the detection threshold in our data, most
likely because the probe for this gene
only tagged two of five isoforms.
(B) Box plot showing the distribution of
allelic ratio at rs6549965 (a SNP in the
RBMS3 transcript) by genotype at
rs11129354 in the presence and absence
of glucocorticoids.
(C) Box plot showing the distribution of
proliferation in PBMCs by treatment and
siRNA.PHA-mediated cellular proliferation in both the presence
(p ¼ 7 3 103) and the absence (p ¼ 3 3 103) of dex
(Figure 3).
Response to glucocorticoid treatment differs across
ethnic groups; on average, AA individuals show weaker
responses to glucocorticoid treatment than do European
American (EA) individuals.10,56 Furthermore, we13 and
others34 observed a tendency for lower sensitivity in
in vitro assays and weaker transcriptional responses across
many genes13 in PBMCs from AA versus EA healthy
donors. We sought to test the contribution of genetic
differentiation to interethnic differences in gluco-The American Journal of Human Gecorticoid sensitivity. To do so, we esti-
mated genome-wide African-ancestry
proportions in each donor by using
STRUCTURE57 and EIGENSTRAT.58
Estimates were highly concordant
between methods (r2 ¼ 0.94) and
consistent with previous studies of
AA individuals (e.g., Pasaniuc et al.59
and Price et al.60), and genome-wide
proportions of African ancestry
showed a median of 81.4% and a
SD of 12.0%. Neither Imax nor IC50
was significantly correlated with
genome-wide proportions of African
ancestry. SNP rs11129354 occurs at
intermediate frequencies globally
and has similar allele frequencies in
Western Europe and West Africa
(proxies for the major ancestral popu-
lations of AA individuals, Figure S3;
frequency of G allele is 0.483 in CEU
[Utah residents with ancestry from
northern and western Europe from
the CEPH collection] and 0.482 in
YRI [Yoruba in Ibadan, Nigeria]), andlocal ancestry at rs11129354 is not significantly associated
(r ¼ 0.11, p ¼ 0.16) with Imax. We hypothesized that this
QTL could reduce the power to detect a correlation
between genome-wide ancestry and Imax by contributing
to variance within ancestral groups without contributing
to differences between them. Consistent with this hypoth-
esis, when we controlled for the effect of this QTL, we
observed a significant correlation between genome-wide
African ancestry and Imax; increasing levels of African
ancestry were associated with lower sensitivity to glucocor-
ticoids (r ¼ 0.23, p ¼ 0.017, Figure S4). This finding is
consistent with clinical10,56 and in vitro13,34 observationsnetics 93, 735–743, October 3, 2013 739
that relative to EA individuals, AA individuals tend to show
weaker responses to glucocorticoids. This directly implies
that ethnic disparities in glucocorticoid treatment
outcome might be due to genetic differentiation between
the ancestral African and European populations. In
contrast, Gould et al. found no significant correlation
between genome-wide African-ancestry proportions and
clinical response to inhaled corticosteroids in individuals
with asthma,61 potentially because of the power reduction
caused by genotype at rs11129354. Alternatively, nonge-
netic factors (i.e., disease severity or compliance with treat-
ment regimens) might have obscured the effect of ancestry
in their study. Additionally, unlike Gould et al., who used a
limited number of ancestry-informative markers, we esti-
mated genome-wide African ancestry on the basis of
genome-wide genotype data, thus affording us greater po-
wer to detect a correlation between ancestry proportions
and lymphocyte glucocorticoid sensitivity.
Glucocorticoids exert their physiological effects through
a multilevel signaling pathway, which is expected to
generate correlations across individuals between pheno-
types measured at each level. We combined multiple levels
of phenotypic information into a single mapping experi-
ment. In addition to mapping genetic determinants at
each of these levels, we were able to take advantage of
the correlation between gene expression and cellular
phenotypes to increase power. The ability to identify
trans-regulatory effects is an especially important benefit
of this approach. For example, we found no significant
evidence of trans-effects in a previous study of glucocorti-
coid interaction expression QTL (eQTL) in lymphoblastoid
cell lines, evenwhenwe focused on a set of candidate genes
that are known regulators of glucocorticoid response.39
Studies of baseline expression in humans have had similar
difficulty in identifying trans-acting eQTL.62,63 This most
likely reflects the need for very strong evidence of associa-
tion to overcome the huge multiple-testing burden
incurred when all polymorphisms are tested against all ex-
pressed genes. In turn, the success of testing candidate
sets of polymorphisms and genes is limited by previous
knowledge of regulatory networks, which is often incom-
plete. Here, we used multiple unbiased scans (genome-
wide polymorphism and transcriptome-wide response) in
tandem to increase power without being limited by previ-
ous knowledge of glucocorticoid biology. For example, in
testing for trans-effects of rs11129354, wewere able to focus
on genes where transcriptional response was correlated
with lymphocyte glucocorticoid sensitivity. This greatly
reduced the number of tests and increased our ability to
identify trans-effects. Testing all expressed genes revealed
one gene where log2 fold change was significantly (FDR <
0.1) correlated with genotype at rs11129354; in contrast,
161 genes were significantly (FDR < 0.1) correlated with
this QTL when we focused only on genes correlated with
lymphocyte glucocorticoid sensitivity. Furthermore, the
observation that genes where transcriptional response was
correlated with lymphocyte glucocorticoid sensitivity also740 The American Journal of Human Genetics 93, 735–743, Octobertended to be correlated with genotype at rs11129354 itself
provides direct statistical support for a model in which
this QTL influences lymphocyte glucocorticoid sensitivity
through its role as a trans-interaction eQTL for these genes.
Future studies of glucocorticoid sensitivity, and other
phenotypes, could incorporate additional levels of pheno-
typic information. These could includemolecular processes
that mediate genotypic effects on expression, as has been
done with DNase I hypersensitivity in HapMap lympho-
blastoid cell lines.64 Genetic association studies of clinical
outcomes could also be integrated with paired molecular
measurements to improve power and provide biological
insights, as discussed in Dermitzakis.65 A similar approach
was successfully employed by a recent study that found
that CD84 (MIM 604513) expression is correlated with dis-
ease activity and that a cis-regulatorypolymorphismfor this
gene is associated with response to entanercept treatment
in individuals with rheumatoid arthritis.66 Eventually, the
combination of many levels of phenotypic information
couldhelp reveal the entire cascadeofmechanisms through
which genetic variation influences variation in glucocorti-
coid insensitivity, as well as other glucocorticoid-related
features of human biological diversity.Supplemental Data
Supplemental Data include four figures and three tables and can
be found with this article online at http://www.cell.com/AJHG.Acknowledgments
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